Source:http://linkedlifedata.com/resource/pubmed/id/12857999
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2-3
|
pubmed:dateCreated |
2003-7-14
|
pubmed:abstractText |
Antigen-presenting cells (APC) can be refaced with "protein paints" that change the appearance of their T cell-oriented trans signal arrays. Our group has developed three categories of protein paints suitable for this kind of APC engineering: artificial glycosylphosphatidylinositol (GPI) proteins, palmitated-protein A:Fc*1 fusion protein conjugates, and trans signal converter proteins. Protein paints have been devised with either immune enhancement or suppression in mind. Costimulator * GPI and palmitated-protein A costimulator * Fcgamma1 conjugates can be used to augment the immune-activating potential of tumor cells. Alternatively, protein paints can be designed to transform APC into artificial veto cells, in essence creating Trojan horses capable of inhibiting pathogenic T cells. Trans signal converter proteins (TSCP) have been devised for this purpose. Our first paradigmatic inhibitory TSCP, CTLA-4 * Fas ligand, binds to APC, and in so doing, simultaneously blocks B7 costimulation (via CTLA-4) and sends inhibitory trans signals (via Fas ligand) to T cells with dramatic efficacy. Protein transfer offers a number of advantages over gene transfer in facilitating quantitative and combinatorial protein expression and simplifying in vivo applications; the palette of protein paints with immunotherapeutic potential will undoubtedly continue to evolve.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0257-277X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
27
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
565-74
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:12857999-Animals,
pubmed-meshheading:12857999-Antigen-Presenting Cells,
pubmed-meshheading:12857999-Cancer Vaccines,
pubmed-meshheading:12857999-Humans,
pubmed-meshheading:12857999-Interleukin-2,
pubmed-meshheading:12857999-Lymphocyte Activation,
pubmed-meshheading:12857999-Membrane Proteins,
pubmed-meshheading:12857999-Protein Engineering,
pubmed-meshheading:12857999-T-Lymphocytes
|
pubmed:year |
2003
|
pubmed:articleTitle |
New designs for cancer vaccine and artificial veto cells: an emerging palette of protein paints.
|
pubmed:affiliation |
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. mlt4@mail.med.upenn.edu
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Review
|